Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
Mario Airoldi, P. Gabriele, C. Bumma(Ospedale San Giovanni Antica Sede), Fulvia Pedani(Ospedale San Giovanni Antica Sede), G Cortesina, Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Luigi Cattel(University of Turin), Carlo Giordano, Silvia Novello(University of Turin)
PubMed
September 11, 2003
Cited by 14
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k